- ICH GCP
- Registro delle prove cliniche dell'UE
Ultime prove
EudraCT Number: 2005-005155-18 | Sponsor Protocol Number: 61/2003/O | Start Date: 2004-02-24 | |||||||||||
Sponsor Name: AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. | |||||||||||||
Medical condition: patients with moderate-strict renal insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001855-12 | Sponsor Protocol Number: BO 18040 | Start Date: 2004-02-16 | ||||||
Sponsor Name: F. Hoffmann-La Roche Ltd | ||||||||
Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ... | ||||||||
Medical condition: Metastatic Bone Pain | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000784-97 | Sponsor Protocol Number: SB-275833/032 | Start Date: 2004-02-16 | |||||||||||
Sponsor Name: GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily, versus Oral Cephalexi... | |||||||||||||
Medical condition: Secondarily-Infected Dermatoses | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004751-38 | Sponsor Protocol Number: om 174 | Start Date: 2004-02-11 | |||||||||||
Sponsor Name: OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma | |||||||||||||
Medical condition: kidney carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003752-38 | Sponsor Protocol Number: om 169 | Start Date: 2003-12-09 | |||||||||||
Sponsor Name: OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer | |||||||||||||
Medical condition: advancer breast carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001055-38 | Sponsor Protocol Number: IELSG20 | Start Date: 2003-11-28 | |||||||||||
Sponsor Name: INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG | |||||||||||||
Full Title: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT ... | |||||||||||||
Medical condition: primary chemotherapy of primary central nervous system lymphoma with high dose cytarabine plus methotrexate | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002113-36 | Sponsor Protocol Number: EORTC 62012 | Start Date: 2003-05-20 | |||||||||||
Sponsor Name: European Organisation for the Research and Treatment of Cancer | |||||||||||||
Full Title: Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma | |||||||||||||
Medical condition: Locally advanced or metastatic soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003746-42 | Sponsor Protocol Number: om 145 | Start Date: 2003-02-11 | |||||||||||
Sponsor Name: OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma | |||||||||||||
Medical condition: metastatic kidney carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002737-21 | Sponsor Protocol Number: om 2002 | Start Date: 2002-09-10 | |||||||||||
Sponsor Name: OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: A randomized phase II study in the advanced or metastatic transitional cell urotelium carcinoma between Gemcitabine + Cisplatin e Gemcitabine + Cisplatino + Taxolo | |||||||||||||
Medical condition: Advanced transitional cell bladder carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002053-69 | Sponsor Protocol Number: 3068A1-301-WW | Start Date: 2002-08-13 | |||||||||||
Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN | |||||||||||||
Medical condition: Reduction of new vertebral fractures in osteoporotic postmenopausal women- Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |